Abstract
The feasibility of preventing cataract by elimination of risk factors or by anti-cataract therapy is reviewed. Elimination of the major risk factors in Western countries would be difficult, although it has potential in the developing world. Various approaches to drug therapy have been made but ran into problems. The development of aldose reductase inhibitors received by far the greatest financial support but problems with toxicity were rapidly followed by the collapse of the original hypothesis. The case of aspirin, paracetamol and ibuprofen built up more slowly with no encouragement from the pharmaceutical industry. Positive results have been achieved in vitro, and in the prevention of diabetic cataract in rats, as well as the identification of an association with a protective effect against cataract in human patients. A clinical trial of these compounds is required. Other anti-cataract agents are also being investigated.
Similar content being viewed by others
Article PDF
References
Minassian DC, Mehra V . 3.8 million blinded by cataract every year: projections from the first epidemiological study of incidence of cataract blindness in India. Br J Ophthalmol 1990;74:341–3.
Pokharel GP, Regmi G, Shrestha SK, Negrel AD, Ellwein LB . Prevalence of blindness and cataract surgery in Nepal. Br J Ophthalmol 1998;82:600–5.
Eckstein M, Vijayalakshmi P, Killedar M, Gilbert C, Foster A . Use of intraocular lenses in children with traumatic cataract in south India. Br J Ophthalmol 1998;82:911–5.
Tielsch JM . Appropriate technology for cataract surgery. Lancet 1998;352:754–5.
Pokharel GP, Selvaraj S, Ellwein LB . Visual functioning and quality of life outcomes among cataract operated and unoperated blind populations in Nepal. Br J Ophthalmol 1998;82:606–10.
Axelsson U . Miotic-induced cataract. Ciba Found Symp 1973;19:249–63.
Pirie A . Chairman's concluding remarks. Ciba Found Symp 1973;19:311–3.
Harding JJ, van Heyningen R . Case-control study of cataract in Oxfordshire. Dev Ophthalmol 1987;15:99–103.
Minassian DC, Mehra V, Verrey JD . Dehydrational crises: a major risk factor in blinding cataract. Br J Ophthalmol 1989;73:100–5.
Crabbe MJC, Goode D . Aldose reductase: a window to the treatment of diabetic complications? Prog Ret Eye Res 1998;17:313–83.
Bron AJ, Brown NAP, Harding JJ, Ganea E . The lens and cataract in diabetes. Int Ophthalmol Clin 1998;38:37–67.
Harding JJ . Cataract: biochemistry, epidemiology and pharmacology. London: Chapman and Hall, 1991.
Cotlier E, Sharma YR . Aspirin and senile cataracts in rheumatoid arthritis. Lancet 1981;I:338–9.
Lin PP, Barry RC, Smith DL, Smith JB . In vivo acetylation identified at lysine 70 of human lens αA-crystallin. Protein Sci 1988;7:1451–7.
Crompton M, Rixon KC, Harding JJ . Aspirin prevents carbamylation of lens proteins and prevents cyanate-induced phase separation opacities in vitro: a possible mechanism by which aspirin could prevent cataract. Exp Eye Res 1985;40:213–222.
Bucala R, Manabe S, Urban RC, Cerami A . Nonenzymatic modification of lens crystallins by prednisolone induces sulfhydryl oxidation and aggregate formation: in vitro and in vivo studies. Exp Eye Res 1985;41:353–63.
Rao GN, Cotlier E . Aspirin prevents the nonenzymatic glycosylation and carbamylation of the human eye lens crystallins in vitro. Biochem Biophys Res Commun 1988;151:991–6.
Huby R, Harding JJ . Non-enzymic glycosylation (glycation) of lens proteins by galactose and protection by aspirin and reduced glutathione. Exp Eye Res 1988;47:53–9.
Ajiboye R, Harding JJ . The non-enzymic glycosylation of bovine lens proteins by glucosamine and its inhibition by aspirin, ibuprofen and glutathione. Exp Eye Res 1989;49:31–41.
Roberts KA, Harding JJ . Ibuprofen, a putative anti-cataract drug, protects the lens against cyanate and galactose. Exp Eye Res 1990;50:157–64.
Raza K, Harding JJ . Non-enzymic modification of lens proteins by glucose and fructose, effects of ibuprofen. Exp Eye Res 1991;52:205–12.
van Heyningen R, Harding JJ . Do aspirin-like drugs protect against cataract? Lancet 1986;I:1111–3.
Harding JJ, van Heyningen R . Drugs including alcohol that act as risk factors for cataract, and possible protection against cataract by aspirin-like analgesics and cyclopenthiazide. Br J Ophthalmol 1988;72:809–14.
Harding JJ, Egerton M, Harding RS . Protection against cataract by aspirin, paracetamol and ibuprofen. Acta Ophthalmol 1989;67:518–24.
Eckerskorn U, Hockwin O, Muller-Breitenkamp R, Chen TT, Knowles W, et al. Evaluation of cataract-related risk factors using detailed classification systems and multivariate statistical methods. Dev Ophthalmol 1987;15:82–91.
Mohan M, Sperduto RD, Surander KA, Milton RC, Mathur RL, et al. India-US case-control study of age-related cataracts. Arch Ophthalmol 1989;107:670–6.
Gupta PP, Pandey DN, Pandey DJ, Sharma AL, Srivastava RK . Aspirin in experimental cataractogenesis. Indian J Med Res 1984;80:703–7.
Swamy MS, Abraham EC . Inhibition of lens crystallin glycation and high molecular weight aggregate formation by aspirin in vitro and in vivo. Invest Ophthalmol Vis Sci 1989;30:1120–6.
Blakytny R, Harding JJ . Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen. Exp Eye Res 1992;54:509–18.
Evans JR, Rauf A, Sayer AA, Wormald RPL, Cooper C . Age-related nuclear lens opacities are associated with reduced growth before one year of age. Invest Ophthalmol Vis Sci 1998;39:1740–4.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harding, J. Can cataract be prevented?. Eye 13, 454–456 (1999). https://doi.org/10.1038/eye.1999.121
Issue Date:
DOI: https://doi.org/10.1038/eye.1999.121
Keywords
This article is cited by
-
Changes in the lens epithelium with respect to cataractogenesis—light microscopic and Scheimpflug densitometric analysis of the cataractous and the clear lens of diabetics and non-diabetics
Graefe's Archive for Clinical and Experimental Ophthalmology (2006)